lapatinib has been researched along with dihydroergotamine in 2 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (dihydroergotamine) | Trials (dihydroergotamine) | Recent Studies (post-2010) (dihydroergotamine) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 1,450 | 241 | 116 |
| Protein | Taxonomy | lapatinib (IC50) | dihydroergotamine (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.09 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 3.9996 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.001 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.0089 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.0039 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.01 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.0007 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 2.395 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.029 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.008 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.09 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.0007 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.0053 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.0068 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.0032 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 2.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for lapatinib and dihydroergotamine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for lapatinib and dihydroergotamine
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |